Bain Capital Life Sciences Investors’s Dianthus Therapeutics DNTH Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.4M	Sell	362,470 -381,122	-51%	-$22.1M	2.74%	8
2025 Q4	$30.6M	Sell	743,592 -572,300	-43%	-$22.2M	2.35%	9
2025 Q3	$51.8M	Sell	1,315,892 -1,166,358	-47%	-$29.8M	3.44%	7
2025 Q2	$46.2M	Sell	2,482,250 -207,457	-8%	-$3.89M	5.79%	5
2025 Q1	$48.8M	Hold	2,689,707	–	–	7.22%	5
2024 Q4	$58.6M	Sell	2,689,707 -323,716	-11%	-$8.32M	6.9%	5
2024 Q3	$82.5M	Hold	3,013,423	–	–	8.58%	4
2024 Q2	$78M	Buy	3,013,423 +21,395	+0.7%	+$514K	8.56%	4
2024 Q1	$89.8M	Buy	+2,992,028	New	+$65M	7.21%	3

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bain Capital Life Sciences Investors's DNTH Position: Q1 2026 in Review

Bain Capital Life Sciences Investors reduced its Dianthus Therapeutics (DNTH) stake by 51% in Q1 2026, selling an estimated $22.1M and leaving 362,470 shares worth $30.4M. The position accounts for 2.74% of the portfolio, ranked #8.

Bain Capital Life Sciences Investors first reported a position in DNTH in Q1 2024 and has held it in 9 quarters since. The position peaked at $89.8M in Q1 2024. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Bain Capital Life Sciences Investors held 362,470 shares of Dianthus Therapeutics worth $30.4M as of Q1 2026.
Bain Capital Life Sciences Investors sold 381,122 Dianthus Therapeutics shares in Q1 2026, an estimated $22.1M.
Dianthus Therapeutics made up 2.74% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #8 holding.
Bain Capital Life Sciences Investors first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 9 quarters since.
Bain Capital Life Sciences Investors's Dianthus Therapeutics position peaked at $89.8M in Q1 2024.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.